Skip to content
    Marshall Wace logo

    Marshall Wace

    London, United KingdomFounded 1997
    www.mwam.comLinkedIn
    Fintech

    Marshall Wace is a London-based global alternative investment manager founded in 1997 by Paul Marshall and Ian Wace. The firm specializes in quantitative, systematic, and fundamental strategies, and has expanded into late-stage venture capital and private equity.

    45% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 7 prior). Average disclosed round size is $128.8M (across 49 rounds with reported amounts).

    Find people at Marshall Wace on Goldilocks AI

    Portfolio

    46

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    3

    Team

    AW

    Albert Wang

    Analyst

    CA

    Corbin Apple

    Analyst

    LE

    Lorenzio Enriquez

    Investment Analyst

    AG

    Andrew Gale

    Investor

    HC

    Hank Carmichael

    Portfolio Manager

    J(

    John (Junyang) Lu

    Portfolio Manager

    RB

    Robbie Bhattacharjee

    Portfolio Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    58 investments
    CompanyRoundAmountDate
    Draig Therapeutics logoDraig TherapeuticsSeries B$65MJul 2026
    Third Arc Bio logoThird Arc BioSeries A$52MFeb 2026
    Aviceda logoAvicedaSeries C—Jan 2026
    AAviceda TherapeuticsUnknown$207.5MJan 2026
    VeraDermics logoVeraDermicsSeries C—Oct 2025
    InspireMD logoInspireMDUnknown$40.1MJul 2025
    Attovia Therapeutics logoAttovia TherapeuticsSeries C$90MApr 2025
    AAviceda TherapeuticsSeries C—Jan 2025
    InspireMD logoInspireMDGrowth$40.1MJan 2025
    35 Pharma logo35 PharmaSeries C$53MNov 2024
    Inquis Medical logoInquis MedicalSeries B$40MNov 2024
    Elektrofi logoElektrofiSeries C$112.3MOct 2024
    Evommune logoEvommuneSeries C$115MOct 2024
    Pathalys logoPathalysSeries B$105MAug 2024
    PPathalys PharmaSeries B$105MAug 2024
    Human Interest logoHuman InterestSeries E$267MJul 2024
    Lycia Therapeutics logoLycia TherapeuticsSeries C$106.6MMay 2024
    Attovia Therapeutics logoAttovia TherapeuticsSeries B$105MMay 2024
    OOnCusp TherapeuticsSeries A$100MJan 2024
    OnCusp logoOnCuspSeries A$100MJan 2024
    Human Interest logoHuman InterestSeries D$200MJan 2024
    Elektrofi logoElektrofiSeries C$152MJan 2024
    Parse Biosciences logoParse BiosciencesSeries C—Dec 2023
    BlueWhale Bio logoBlueWhale BioSeed$18MSep 2023
    ADARx Pharmaceuticals logoADARx PharmaceuticalsSeries C$200MAug 2023
    Page 1 of 3

    Top Co-Investors

    Logos Capital16 shared
    OrbiMed14 shared
    venBio9 shared
    The Invus Group, LLC7 shared
    RA Capital Management7 shared
    BlackRock Private Equity Partners7 shared
    Vivo Capital7 shared
    Catalio Capital Management6 shared
    Surveyor Capital6 shared
    Cormorant Asset Management5 shared
    SR One5 shared
    Bain Capital Life Sciences5 shared
    Deep Track Capital5 shared
    Samsara BioCapital5 shared
    Novo Capital5 shared
    RTW Investments, LP5 shared
    Soleus Capital5 shared
    Omega Funds4 shared
    General Catalyst4 shared
    Venrock Healthcare Capital Partners4 shared

    Last updated: 7 October 2026